Andere talen Zhongsheng Group Holdings Limited

Aandelen

881 KYG9894K1085

Beurs gesloten - Hong Kong Stock Exchange Andere beurzen 09:08:29 29-11-2023			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
18,12 ^HKD	-2,37%		-6,60%	-54,87%

02/11	Tiantan Biological Products verkrijgt opnieuw een licentie voor bloedinzameling	MT
18/10	Zhongsheng Pharmaceutical krijgt geneesmiddelregistratiecertificaat voor orale carbocysteïneoplossing	MT

Andere talen

Ontgrendel al het nieuws over alle bedrijven: Mis nooit meer een winstgevende investeringskans!

Gratis inschrijven

Tiantan Biological Products Secures Another Blood Collection License	02/11
Zhongsheng Pharmaceutical Gets Drug Registration Certificate for Carbocysteine Oral Solution	18/10
Middle East Turmoil, Crude Prices Roil Asian Markets in Holiday-Thinned Trading	09/10
Beijing Tiantan Biological Products Lands Blood Collection License in China’s Liping County	15/09
Zhongsheng Group's Profit Drops 12.8% in H1	24/08
Zhongsheng Group Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23/08
Bargain Hunting Lifts Asian Stock Markets	22/08
Zhongsheng Pharmaceutical Gets Nod to Register Moxifloxacin Hydrochloride Eye Drops	31/07
Chairman, Controlling Shareholder Boosts Stake in Zhongsheng Group	20/07
Zhongsheng Group Holdings Limited commences an Equity Buyback Plan for 240,182,336 shares, representing 10% of its issued share capital, under the authorization approved on June 19, 2023.	12/07
Zhongsheng Pharma Registers Mucolytic in China	06/07
China Services Outlook Blunts Asian Stock Markets	05/07
Zhongsheng Pharmaceutical Unit Completes Phase III Clinical Trial of Flu Drug	03/07
Zhongsheng Group Slashes Conversion Price of HK$4.56 Billion Convertible Bonds	20/06
Zhongsheng Group Holdings Limited Approves Final Dividend for the Year Ended 31 December 2022, Payable on July 14, 2023	19/06
Zhongsheng Group Holdings Limited's Equity Buyback announced on August 31, 2022, has expired.	19/06
Zhongsheng Pharma Enrols Subjects in Phase IIb Clinical Trial of NASH Drug	05/06
Zhongsheng Group Buys Back 10.2 Million Shares	31/05
Zhongsheng Group Holdings CEO Boosts Shareholding	31/05
Zhongsheng Pharm Unit Enrolls First Subject for RAY1225 Injection Trial	22/05

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel Artikel MarketScreener Analyse MarketScreener

Andere talen Zhongsheng Group Holdings Limited

Aandelen

881

KYG9894K1085

Andere talen

Filters